Celestial Biolabs Limited is a Public incorporated on 19 November 1997. It is classified as non-govt company and is registered at Registrar of Companies, Hyderabad. Its authorized share capital is Rs. 290,000,000 and its paid-up capital is Rs. 225,863, 500.and its main work is herbal and seed supplement formulation. And the company get delisted in 2015 by SEBI. And the current status of company is active.
|
Celestial Biolabs Limited Outstanding Shares: |
2,25,86,350 |
|
Face Value of Celestial Biolabs Limited Share: |
10.00 |
|
ISIN of Celestial Biolabs Limited Share: |
INE221101017 |
|
Lot Size of Celestial Biolabs Limited Share: |
100 |
|
Celestial Biolabs Limited Share Price: |
Best In Industry |
|
PAN Number of Celestial Biolabs Limited: |
AABCC4698Q |
|
GST Number of Celestial Biolabs Limited: |
36AABCC4698Q1ZV |
|
Celestial Biolabs Limited CIN Number |
L72200TG1997PLC028374 |
|
GST Number |
36AABCC4698Q1ZV |
|
Celestial Biolabs Limited Registration Date |
19-Nov-97 |
|
Category / Sub-Category of Celestial Biolabs Limited |
Non-govt company |
|
Celestial Biolabs Limited Registered Office Address |
PLOT NO. 59, ROAD NO. 12, APIIC TECH PARK, IDA NACHARAM HYDERABAD TG 500076 IN. |
|
Directors |
Post |
|
Dr. A N Singh |
Managing Director, Executive & Non-Independent |
|
Mr. Amit Kumar Singh |
Managing Director, Executive & Non-Independent |
|
Dr.D.C. Sastry |
Independent & Non-Executive Dr. A P Rao |
|
Dr. A P Rao |
Independent & non-executive |
|
Smt.Padma Singh |
Non-Independent & Non-Executive |
|
S. No. |
Name and Description of main products/Services |
NIC Code of the Product /Service |
% to total turnover of the Company |
|
1 |
Herbal and seed supplement formulation |
3004 & 2309 |
100.00% |
|
Category |
No. of Shares |
% of Shares held |
|
promoters |
58,88,963 |
26.07% |
|
Public Shareholding |
1,66,97,387 |
73.93% |
|
Total |
2,25,86,350 |
100.00% |
FAQs on Celestial Biolabs Ltd
Q: What is the face value of Celestial Biolabs Ltd shares?
Answer: The face value of Celestial Biolabs Ltd is ₹10 per equity share.
Q: What is the minimum lot size for buying Celestial Biolabs shares through WWIPL?
Answer: The minimum lot size for Celestial Biolabs shares is 100 equity shares.
Q: How can I buy Celestial Biolabs unlisted shares through WWIPL?
Answer: Investors can complete the KYC process, confirm the transaction details with WWIPL, transfer funds, and receive shares directly in their Demat account.
Q: Why should I buy Celestial Biolabs shares through WWIPL?
Answer: WWIPL offers transparent pricing, secure transactions, seamless Demat transfers, and dedicated support throughout the investment process.
Q: Is investing in Celestial Biolabs Ltd a good idea?
Answer: Investors often evaluate Celestial Biolabs based on its pharmaceutical and nutraceutical business, financial performance, valuation, and long-term growth potential before making an investment decision.
Q: Why do investors buy Celestial Biolabs shares before a potential IPO?
Answer: Investors seek exposure to an established pharmaceutical company in the unlisted market, with the expectation of long-term value creation through future business growth and corporate developments.
Q: What business does Celestial Biolabs Ltd operate in?
Answer: Celestial Biolabs is engaged in the manufacture of herbal formulations and seed supplement products, serving the pharmaceutical and nutraceutical sectors.
Q: Who founded Celestial Biolabs Ltd?
Answer: Celestial Biolabs Ltd was incorporated on 19 November 1997 and operates as an Indian pharmaceutical company.
Q: What makes Celestial Biolabs different from other unlisted pharmaceutical companies?
Answer: The company focuses on herbal formulations and seed supplement products, offering exposure to niche segments within the healthcare and nutraceutical industry.
Q: What are the key growth drivers for Celestial Biolabs Ltd?
Answer: Demand for herbal healthcare products, expansion of nutraceuticals, product innovation, regulatory approvals, and improving operational performance are key growth drivers.
Q: What factors affect the valuation of Celestial Biolabs shares?
Answer: Revenue growth, profitability, product portfolio, regulatory compliance, manufacturing capabilities, market demand for unlisted shares, and future corporate developments are important valuation drivers.
Q: Are Celestial Biolabs shares available in Demat form?
Answer: Yes. Shares purchased through WWIPL are transferred directly to the investor's Demat account.
Q: Can I sell my Celestial Biolabs shares through WWIPL?
Answer: Yes. WWIPL facilitates both buying and selling of unlisted shares, subject to market demand and share availability.
Q: What documents are required to buy Celestial Biolabs shares through WWIPL?
Answer: Investors generally need PAN, Aadhaar, Client Master Report (CMR), and bank account details to complete the transaction.
Q: What are the risks of investing in Celestial Biolabs shares?
Answer: Investors should consider regulatory risks, product approval risks, competition, operational performance, profitability fluctuations, and the liquidity constraints associated with unlisted shares.
Q: How does WWIPL help investors track Celestial Biolabs investments?
Answer: WWIPL provides company updates, transaction assistance, market information, and investment insights to help investors stay informed.
Q: How long does it take for Celestial Biolabs shares purchased through WWIPL to be credited to a Demat account?
Answer: Shares are generally transferred to the investor's Demat account after successful completion and verification of the transaction.
Q: What should investors evaluate before investing in Celestial Biolabs Ltd?
Answer: Investors should assess the company's financial performance, product portfolio, regulatory compliance, profitability, valuation, balance sheet strength, and long-term growth prospects.
Q: Can Celestial Biolabs benefit from India's growing pharmaceutical and nutraceutical industry?
Answer: Yes. Rising healthcare awareness, increasing demand for herbal and nutraceutical products, and continued growth in the pharmaceutical sector may create significant long-term growth opportunities for the company.
